Helmerich & Payne Inc. Common Stock vs Heron Therapeutics Inc — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.91B), while Heron Therapeutics Inc trades at $0.36 (market cap $74.18M). The key difference: Helmerich & Payne Inc. Common Stock is far larger — about 52.7× Heron Therapeutics Inc's market cap, and Helmerich & Payne Inc. Common Stock pays a 2.56% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and Heron Therapeutics Inc for 36 Days on average.
| HP | HRTX | |
|---|---|---|
Market Cap | $3.91B | $74.18M |
Volume | 800,382 | 1,857,401 |
Sector | Energy | Health |
52-Week High | $47.64 | $1.49 |
52-Week Low | $23.11 | $0.27 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $5.54B | $180.92M |
Dividend Yield | 2.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.
Read more on HP →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →